10x Genomics (TXG) Panoramica del titolo
10x Genomics, Inc. sviluppa e vende strumenti, materiali di consumo e software per l'analisi di sistemi biologici negli Stati Uniti, nel resto delle Americhe, in Europa, nel Medio Oriente, in Africa, in Cina e nel resto dell'Asia Pacifica. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
TXG Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di 10x Genomics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$79.10 |
| Massimo di 52 settimane | US$80.11 |
| Minimo di 52 settimane | US$11.16 |
| Beta | 2.08 |
| Variazione di 1 mese | 21.47% |
| Variazione a 3 mesi | 148.20% |
| Variazione di 1 anno | 506.60% |
| Variazione a 3 anni | 91.94% |
| Variazione a 5 anni | -48.09% |
| Variazione dall'IPO | 49.95% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 17
TXG: Rich Multiples Will Clash With Slower Single Cell Recovery Expectations
The analyst price target framework for 10x Genomics has shifted higher, with fair value moving from $17.00 to $40.00 as analysts factor in updated growth assumptions, higher projected profit margins, and richer sector P/E multiples supported by recent research that highlights Atera demand, consumable durability, and the broader life science tools backdrop. Analyst Commentary Recent research coverage on 10x Genomics shows a mix of optimism around new products and a more measured stance on the company’s more established lines of business.
Aggiornamento narrativa • Sep 03
TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook
The analyst price target for 10x Genomics has moved from $50 to about $68, with analysts pointing to updated models that reflect the Atera launch, spatial and consumables demand, and the company's positioning around AI driven drug development as key supports for the higher valuation assumptions. Analyst Commentary Recent Street research on 10x Genomics points to a cluster of price target increases tied to Atera, spatial biology adoption, and updated revenue models.Recent updates
Aggiornamento narrativa • Sep 17
TXG: Rich Multiples Will Clash With Slower Single Cell Recovery Expectations
The analyst price target framework for 10x Genomics has shifted higher, with fair value moving from $17.00 to $40.00 as analysts factor in updated growth assumptions, higher projected profit margins, and richer sector P/E multiples supported by recent research that highlights Atera demand, consumable durability, and the broader life science tools backdrop. Analyst Commentary Recent research coverage on 10x Genomics shows a mix of optimism around new products and a more measured stance on the company’s more established lines of business.Aggiornamento narrativa • Sep 03
TXG: Cancer Collaborations And AI Drug Discovery Uses Will Shape Balanced Outlook
The analyst price target for 10x Genomics has moved from $50 to about $68, with analysts pointing to updated models that reflect the Atera launch, spatial and consumables demand, and the company's positioning around AI driven drug development as key supports for the higher valuation assumptions. Analyst Commentary Recent Street research on 10x Genomics points to a cluster of price target increases tied to Atera, spatial biology adoption, and updated revenue models.
Aggiornamento narrativa • Aug 20
TXG: Elevated AI Demand Expectations Will Pressure Overextended Near Term Setup
Analysts have lifted the fair value estimate for 10x Genomics from $41.54 to $49.54, reflecting a series of higher price targets that reference stronger revenue assumptions, slightly improved profit margins, and interest in the company's role in AI driven drug development and Atera demand. Analyst Commentary Recent Street research on 10x Genomics points to a mix of optimism and caution.Seeking Alpha • Aug 20
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
Summary Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG’s valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution. Read the full article on Seeking AlphaArticolo di analisi • Aug 12
US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results
A week ago, 10x Genomics, Inc. ( NASDAQ:TXG ) came out with a strong set of quarterly numbers that could potentially...Aggiornamento narrativa • Aug 06
TXG: Elevated 2027 Expectations And Product Transitions Will Pressure Near Term Setup
Analyst price targets for 10x Genomics have moved sharply higher, with the fair value estimate rising from about $20.14 to $41.54 as analysts factor in higher sector multiples, expectations around single cell demand, and potential contribution from the Atera platform in coming years. Analyst Commentary Recent research on 10x Genomics shows a cluster of higher price targets, but with mixed views on how much upside is left relative to execution risk and current valuation levels.Aggiornamento narrativa • Jul 23
TXG: Cancer Collaboration And Tools Strength Will Support Balanced Outlook
The analyst price target for 10x Genomics has been raised from $45.00 to $50.00. Analysts generally point to higher sector multiples, expectations that single cell and the Atera platform could support future demand, and updated earnings models ahead of upcoming results as key reasons for the change.Aggiornamento narrativa • Jul 09
TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook
Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.Aggiornamento narrativa • Jun 25
TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook
Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.Aggiornamento narrativa • Jun 11
TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook
Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.Aggiornamento narrativa • May 28
TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026
Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.Articolo di analisi • May 13
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results
10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...Aggiornamento narrativa • May 12
TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations
Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.Aggiornamento narrativa • Apr 21
TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026
The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.Aggiornamento narrativa • Apr 06
TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook
Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.Aggiornamento narrativa • Mar 23
TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup
Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.Aggiornamento narrativa • Mar 07
TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations
Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.Aggiornamento narrativa • Feb 21
TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment
The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.Aggiornamento narrativa • Feb 07
TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside
Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.Articolo di analisi • Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...Aggiornamento narrativa • Jan 23
TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential
Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.Aggiornamento narrativa • Jan 08
TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment
Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.Aggiornamento narrativa • Dec 25
TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance
Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.Aggiornamento narrativa • Dec 11
TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook
Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.Aggiornamento narrativa • Nov 27
TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure
Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.Articolo di analisi • Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...Aggiornamento narrativa • Nov 09
TXG: Institutional Interest And New Assay Expected To Influence Future Performance
Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.Aggiornamento narrativa • Aug 08
Advanced Genomics Tools Will Shape Future Precision Medicine
Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.Rendimenti per gli azionisti
| TXG | US Life Sciences | US Mercato | |
|---|---|---|---|
| 7D | 12.8% | 6.5% | 1.8% |
| 1Y | 506.6% | 34.2% | 13.3% |
Ritorno vs Industria: TXG ha superato il US Life Sciences che ha restituito 34.2 % nell'ultimo anno.
Rendimento vs Mercato: TXG ha superato il mercato US che ha restituito 13.3 % nell'ultimo anno.
Volatilità dei prezzi
| TXG volatility | |
|---|---|
| TXG Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Prezzo delle azioni stabile: TXG non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 10% ) di TXG è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2012 | 1,178 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc. sviluppa e vende strumenti, materiali di consumo e software per l'analisi di sistemi biologici negli Stati Uniti, nel resto delle Americhe, in Europa, nel Medio Oriente, in Africa, in Cina e nel resto dell'Asia Pacifica. L'azienda offre la piattaforma Chromium, un portafoglio di singole cellule che consente l'analisi di singoli componenti biologici, oltre a includere chip microfluidici e relativi materiali di consumo, la serie Chromium X e gli strumenti Chromium; e i kit QuantumScale per l'RNA di singole cellule e la metilazione di singole cellule. Fornisce inoltre la piattaforma Visium, una piattaforma di analisi spaziale che utilizza array di DNA ad alta densità per codificare la posizione fisica degli analiti biologici all'interno di un campione.
10x Genomics, Inc. Riepilogo dei fondamenti
| TXG statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$9.98b |
| Utili (TTM) | -US$75.12m |
| Ricavi(TTM) | US$616.91m |
16.7x
Rapporto P/S-137.2x
Rapporto P/ETXG è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| TXG Conto economico (TTM) | |
|---|---|
| Ricavi | US$616.91m |
| Costo del fatturato | US$184.38m |
| Profitto lordo | US$432.53m |
| Altre spese | US$507.65m |
| Utili | -US$75.12m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.58 |
| Margine lordo | 70.11% |
| Margine di profitto netto | -12.18% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato TXG nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 10:01 |
| Prezzo dell'azione a fine giornata | 2026/09/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
10x Genomics, Inc. è coperta da 26 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Luke Sergott | Barclays |
| Avantika Dhabaria | BofA Global Research |
| Michael Ryskin | BofA Global Research |